
@article{Johnson:2017:Enabling,
  title = {Enabling {{Precision Cardiology Through Multiscale Biology}} and {{Systems Medicine}}},
  volume = {2},
  issn = {2452-302X},
  doi = {10.1016/j.jacbts.2016.11.010},
  abstract = {The traditional paradigm of cardiovascular disease research derives insight from large-scale, broadly inclusive clinical studies of well-characterized pathologies. These insights are then put into practice according to standardized clinical guidelines. However, stagnation in the development of new cardiovascular therapies and variability in therapeutic response implies that this paradigm is insufficient for reducing the cardiovascular disease burden. In this state-of-the-art review, we~examine 3 interconnected ideas we put forth as key concepts for enabling a transition to precision cardiology: 1)~precision~characterization of cardiovascular disease with machine learning methods; 2) the application of network models of disease to embrace disease complexity; and 3) using insights from the previous 2 ideas to enable pharmacology and polypharmacology systems for more precise drug-to-patient matching and patient-disease stratification. We conclude by exploring the challenges of applying a precision approach to cardiology, which arise from a deficit of the required resources and infrastructure, and emerging evidence for the clinical effectiveness of this nascent approach.},
  number = {3},
  journal = {JACC: Basic to Translational Science},
  author = {Johnson, Kipp W. and Shameer, Khader and Glicksberg, Benjamin S. and Readhead, Ben and Sengupta, Partho P. and Bj\"orkegren, Johan L.M. and Kovacic, Jason C. and Dudley, Joel T.},
  month = jun,
  year = {2017},
  pages = {311-327},
  pmid = {30062151},
  pmcid = {PMC6034501}
}

@article{Denaxas:2015:Big,
  title = {Big Biomedical Data and Cardiovascular Disease Research: Opportunities and Challenges},
  volume = {1},
  issn = {2058-5225},
  shorttitle = {Big Biomedical Data and Cardiovascular Disease Research},
  doi = {10.1093/ehjqcco/qcv005},
  abstract = {Abstract.  Electronic health records (EHRs), data generated and collected during normal clinical care, are increasingly being linked and used for translational},
  language = {en},
  number = {1},
  journal = {European Heart Journal - Quality of Care and Clinical Outcomes},
  author = {Denaxas, Spiros C. and Morley, Katherine I.},
  month = jul,
  year = {2015},
  pages = {9-16}
}

@article{Dainis:2018:Cardiovascular,
  title = {Cardiovascular {{Precision Medicine}} in the {{Genomics Era}}},
  volume = {3},
  issn = {2452-302X},
  doi = {10.1016/j.jacbts.2018.01.003},
  abstract = {Precision medicine strives to delineate disease using multiple data sources\textemdash{}from genomics to digital health metrics\textemdash{}in order to be more precise and accurate in our diagnoses, definitions, and treatments of disease subtypes. By defining disease at a deeper level, we can treat patients based on an understanding of the molecular underpinnings of their presentations, rather than grouping patients into broad categories with one-size-fits-all treatments. In this review, the authors examine how precision medicine, specifically that surrounding genetic testing and genetic therapeutics, has begun to make strides in both common and rare cardiovascular diseases in the clinic and the laboratory, and how these advances are beginning to enable us to more effectively define risk, diagnose disease, and deliver therapeutics for each~individual patient.},
  number = {2},
  journal = {JACC: Basic to Translational Science},
  author = {Dainis, Alexandra M. and Ashley, Euan A.},
  month = may,
  year = {2018},
  pages = {313-326},
  pmid = {30062216},
  pmcid = {PMC6059349}
}

@article{Parikh:2017:Next,
  title = {Next {{Generation Sequencing}} in {{Cardiovascular Disease}}: {{Present Clinical Applications}} and the {{Horizon}} of {{Precision Medicine}}},
  volume = {135},
  issn = {0009-7322},
  shorttitle = {Next {{Generation Sequencing}} in {{Cardiovascular Disease}}},
  doi = {10.1161/CIRCULATIONAHA.116.024258},
  number = {5},
  journal = {Circulation},
  author = {Parikh, Victoria N. and Ashley, Euan A.},
  month = jan,
  year = {2017},
  pages = {406-409},
  pmid = {28137961},
  pmcid = {PMC5310819}
}

@article{Adler:2018:PhenoDis,
  title = {{{PhenoDis}}: A Comprehensive Database for Phenotypic Characterization of Rare Cardiac Diseases},
  volume = {13},
  issn = {1750-1172},
  shorttitle = {{{PhenoDis}}},
  doi = {10.1186/s13023-018-0765-y},
  abstract = {BACKGROUND: Thoroughly annotated data resources are a key requirement in phenotype dependent analysis and diagnosis of diseases in the area of precision medicine. Recent work has shown that curation and systematic annotation of human phenome data can significantly improve the quality and selectivity for the interpretation of inherited diseases. We have therefore developed PhenoDis, a comprehensive, manually annotated database providing symptomatic, genetic and imprinting information about rare cardiac diseases.
RESULTS: PhenoDis includes 214 rare cardiac diseases from Orphanet and 94 more from OMIM. For phenotypic characterization of the diseases, we performed manual annotation of diseases with articles from the biomedical literature. Detailed description of disease symptoms required the use of 2247 different terms from the Human Phenotype Ontology (HPO). Diseases listed in PhenoDis frequently cover a broad spectrum of symptoms with 28\% from the branch of 'cardiovascular abnormality' and others from areas such as neurological (11.5\%) and metabolism (6\%). We collected extensive information on the frequency of symptoms in respective diseases as well as on disease-associated genes and imprinting data. The analysis of the abundance of symptoms in patient studies revealed that most of the annotated symptoms (71\%) are found in less than half of the patients of a particular disease. Comprehensive and systematic characterization of symptoms including their frequency is a pivotal prerequisite for computer based prediction of diseases and disease causing genetic variants. To this end, PhenoDis provides in-depth annotation for a complete group of rare diseases, including information on pathogenic and likely pathogenic genetic variants for 206 diseases as listed in ClinVar. We integrated all results in an online database ( http://mips.helmholtz-muenchen.de/phenodis/ ) with multiple search options and provide the complete dataset for download.
CONCLUSION: PhenoDis provides a comprehensive set of manually annotated rare cardiac diseases that enables computational approaches for disease prediction via decision support systems and phenotype-driven strategies for the identification of disease causing genes.},
  language = {eng},
  number = {1},
  journal = {Orphanet Journal of Rare Diseases},
  author = {Adler, Angela and Kirchmeier, Pia and Reinhard, Julian and Brauner, Barbara and Dunger, Irmtraud and Fobo, Gisela and Frishman, Goar and Montrone, Corinna and Mewes, H.-Werner and Arnold, Matthias and Ruepp, Andreas},
  month = jan,
  year = {2018},
  keywords = {Genotype,Medical genetics,Phenotype,Bioinformatics,Decision support systems,Genetic disorders,Heart,Personalized medicine,Precision medicine,Rare cardiac diseases},
  pages = {22},
  pmid = {29370821},
  pmcid = {PMC5785853}
}

@misc{Shi:2014:Phenomics,
  type = {Research Article},
  title = {Phenomics {{Research}} on {{Coronary Heart Disease Based}} on {{Human Phenotype Ontology}}},
  abstract = {The characteristics of holistic, dynamics, complexity, and spatial and temporal features enable ``Omics'' and theories of TCM to interlink with each other. HPO, namely, ``characterization,'' can be understood as a sorting and generalization of the manifestations shown by people with diseases on the basis of the phenomics. Syndrome is the overall ``manifestation'' of human body pathological and physiological changes expressed by four diagnostic methods' information. The four diagnostic methods' data could be the most objective and direct manifestations of human body under morbid conditions. In this aspect, it is consistent with the connation of ``characterization.'' Meanwhile, the four diagnostic methods' data also equip us with features of characterization in HPO. In our study, we compared 107 pieces of four diagnostic methods' information with the ``characterization database'' to further analyze data of four diagnostic methods' characterization in accordance with the common characteristics of four diagnostic methods' information and characterization and integrated 107 pieces of four diagnostic methods' data to relevant items in HPO and finished the expansion of characterization information in HPO.},
  language = {en},
  howpublished = {https://www.hindawi.com/journals/bmri/2014/240284/},
  journal = {BioMed Research International},
  author = {Shi, Qi and Gao, Kuo and Zhao, Huihui and Wang, Juan and Zhai, Xing and Lu, Peng and Chen, Jianxin and Wang, Wei},
  year = {2014},
  doi = {10.1155/2014/240284}
}

@article{Wang:2018:HDncRNA,
  title = {{{HDncRNA}}: A Comprehensive Database of Non-Coding {{RNAs}} Associated with Heart Diseases},
  volume = {2018},
  shorttitle = {{{HDncRNA}}},
  doi = {10.1093/database/bay067},
  abstract = {Abstract.  Heart diseases (HDs) represent a common group of diseases that involve the heart, a number of which are characterized by high morbidity and lethality},
  language = {en},
  journal = {Database},
  author = {Wang, Wen-Jing and Wang, Yu-Mei and Hu, Yi and Lin, Qin and Chen, Rou and Liu, Huan and Cao, Wen-Ze and Zhu, Hui-Fang and Tong, Chang and Li, Li and Peng, Lu-Ying},
  month = jan,
  year = {2018}
}

@article{Austin:2013:Using,
  title = {Using Methods from the Data-Mining and Machine-Learning Literature for Disease Classification and Prediction: A Case Study Examining Classification of Heart Failure Subtypes},
  volume = {66},
  issn = {0895-4356},
  shorttitle = {Using Methods from the Data-Mining and Machine-Learning Literature for Disease Classification and Prediction},
  doi = {10.1016/j.jclinepi.2012.11.008},
  abstract = {Objective
Physicians classify patients into those with or without a specific disease. Furthermore, there is often interest in classifying patients according to disease etiology or subtype. Classification trees are frequently used to classify patients according to the presence or absence of a disease. However, classification trees can suffer from limited accuracy. In the data-mining and machine-learning literature, alternate classification schemes have been developed. These include bootstrap aggregation (bagging), boosting, random forests, and support vector machines.
Study Design and Setting
We compared the performance of these classification methods with that of conventional classification trees to classify patients with heart failure (HF) according to the following subtypes: HF with preserved ejection fraction (HFPEF) and HF with reduced ejection fraction. We also compared the ability of these methods to predict the probability of the presence of HFPEF with that of conventional logistic regression.
Results
We found that modern, flexible tree-based methods from the data-mining literature offer substantial improvement in prediction and classification of HF subtype compared with conventional classification and regression trees. However, conventional logistic regression had superior performance for predicting the probability of the presence of HFPEF compared with the methods proposed in the data-mining literature.
Conclusion
The use of tree-based methods offers superior performance over conventional classification and regression trees for predicting and classifying HF subtypes in a population-based sample of patients from Ontario, Canada. However, these methods do not offer substantial improvements over logistic regression for predicting the presence of HFPEF.},
  number = {4},
  journal = {Journal of Clinical Epidemiology},
  author = {Austin, Peter C. and Tu, Jack V. and Ho, Jennifer E. and Levy, Daniel and Lee, Douglas S.},
  month = apr,
  year = {2013},
  keywords = {Classification,Bagging,Boosting,Classification trees,Heart failure,Prediction,Random forests,Regression methods,Regression trees,Support vector machines},
  pages = {398-407}
}

@article{Vilne:2018:Integrating,
  title = {Integrating {{Genes Affecting Coronary Artery Disease}} in {{Functional Networks}} by {{Multi}}-{{OMICs Approach}}},
  volume = {5},
  issn = {2297-055X},
  doi = {10.3389/fcvm.2018.00089},
  abstract = {Coronary artery disease (CAD) and myocardial infarction (MI) remain among the leading causes of mortality worldwide, urgently demanding a better understanding of disease etiology and more efficient therapeutic strategies. Genetic predisposition as well as the environment and lifestyle are thought to contribute to disease risk. It is likely that non-linear and complex interactions occur between these multiple factors, involving simultaneous pathological changes in diverse cell types, tissues and organs, at multiple molecular levels. Recent technological advances have exponentially expanded the breadth of available -omics data, from genome, epigenome, transcriptome, proteome, metabolome to even the microbiome. Integration of multiple layers of information across several -omics domains, i.e. the so-called multi-omics approach, currently holds the promise as a path towards precision medicine. Indeed, a more meaningful interpretation of genotype-phenotype relationships and the development of successful therapeutics tailored to individual patients are urgently needed. In this review, we will summarize recent findings and applications of integrative multi-omics in elucidating the etiology of CAD/MI; with a special focus on established disease susceptibility loci sequentially identified in genome-wide association studies (GWAS) over the last ten years. Moreover, in addition to the autosomal genome, we will also consider the genetic variation in our ``second genome'' - the mitochondrial genome. Finally, we will summarize the current challenges in the field and point to future research directions required in order to successfully and effectively apply these approaches for precision medicine.},
  language = {English},
  journal = {Frontiers in Cardiovascular Medicine},
  author = {Vilne, Baiba and Schunkert, Heribert},
  year = {2018},
  keywords = {Transcriptomics,Epigenomics,Metabolomics,cardiovascular disease,Genomics,Integrative Genomics,microbiomics,Multi-omics integration,Proteomics}
}

@article{Cg:00:00:00.0:Cardiac,
  title = {The {{Cardiac Atlas Project}}--an Imaging Database for Computational Modeling and Statistical Atlases of the Heart.},
  volume = {27},
  doi = {10.1093/bioinformatics/btr360},
  abstract = {Read the latest recommendation by John Jeremy Rice and Raquel Norel from the Physiology Faculty, at F1000Prime.},
  language = {en},
  number = {16},
  journal = {Bioinformatics},
  author = {Cg, Fonseca and M, Backhaus and Da, Bluemke and Rd, Britten and Jd, Chung and Br, Cowan and Id, Dinov and Jp, Finn and Pj, Hunter and Ah, Kadish and Dc, Lee and Ja, Lima and P, Medrano-Gracia and K, Shivkumar and A, Suinesiaputra and W, Tao and Aa, Young and Cg, Fonseca and M, Backhaus and Da, Bluemke and Rd, Britten and Jd, Chung and Br, Cowan and Id, Dinov and Jp, Finn and Pj, Hunter and Ah, Kadish and Dc, Lee and Ja, Lima and P, Medrano-Gracia and K, Shivkumar and A, Suinesiaputra and W, Tao and Aa, Young},
  year = {00:00:00.0},
  pmid = {21737439}
}

@article{Kass-Hout:2018:American,
  title = {American {{Heart Association Precision Medicine Platform}}},
  volume = {137},
  issn = {0009-7322, 1524-4539},
  doi = {10.1161/CIRCULATIONAHA.117.032041},
  language = {en},
  number = {7},
  journal = {Circulation},
  author = {{Kass-Hout}, Taha A. and Stevens, Laura M. and Hall, Jennifer L.},
  month = feb,
  year = {2018},
  pages = {647-649}
}

@misc{Boulton:2016:Reproducibility,
  type = {Comments and {{Opinion}}},
  title = {Reproducibility: {{International}} Accord on Open Data},
  copyright = {2016 Nature Publishing Group},
  shorttitle = {Reproducibility},
  abstract = {Reproducibility: International accord on open data},
  language = {en},
  howpublished = {https://www.nature.com/articles/530281c},
  journal = {Nature},
  author = {Boulton, Geoffrey},
  month = feb,
  year = {2016},
  doi = {10.1038/530281c}
}

@article{Wilkinson:2016:FAIR,
  title = {The {{FAIR Guiding Principles}} for Scientific Data Management and Stewardship},
  volume = {3},
  issn = {2052-4463},
  doi = {10.1038/sdata.2016.18},
  language = {en},
  journal = {Scientific Data},
  author = {Wilkinson, Mark D. and Dumontier, Michel and Aalbersberg, IJsbrand Jan and Appleton, Gabrielle and Axton, Myles and Baak, Arie and Blomberg, Niklas and Boiten, Jan-Willem and {da Silva Santos}, Luiz Bonino and Bourne, Philip E. and Bouwman, Jildau and Brookes, Anthony J. and Clark, Tim and Crosas, Merc\`e and Dillo, Ingrid and Dumon, Olivier and Edmunds, Scott and Evelo, Chris T. and Finkers, Richard and {Gonzalez-Beltran}, Alejandra and Gray, Alasdair J.G. and Groth, Paul and Goble, Carole and Grethe, Jeffrey S. and Heringa, Jaap and {'t Hoen}, Peter A.C and Hooft, Rob and Kuhn, Tobias and Kok, Ruben and Kok, Joost and Lusher, Scott J. and Martone, Maryann E. and Mons, Albert and Packer, Abel L. and Persson, Bengt and {Rocca-Serra}, Philippe and Roos, Marco and {van Schaik}, Rene and Sansone, Susanna-Assunta and Schultes, Erik and Sengstag, Thierry and Slater, Ted and Strawn, George and Swertz, Morris A. and Thompson, Mark and {van der Lei}, Johan and {van Mulligen}, Erik and Velterop, Jan and Waagmeester, Andra and Wittenburg, Peter and Wolstencroft, Katherine and Zhao, Jun and Mons, Barend},
  month = mar,
  year = {2016},
  pages = {160018}
}

@article{Lau:2016:Connecting,
  title = {Connecting the {{Dots}}: {{From Big Data}} to {{Healthy Heart}}},
  volume = {134},
  issn = {0009-7322},
  shorttitle = {Connecting the {{Dots}}},
  doi = {10.1161/CIRCULATIONAHA.116.021892},
  number = {5},
  journal = {Circulation},
  author = {Lau, Edward and Watson, Karol E. and Ping, Peipei},
  month = aug,
  year = {2016},
  pages = {362-364},
  pmid = {27481999},
  pmcid = {PMC5096589}
}

@article{Shameer:2018:Machine,
  title = {Machine Learning in Cardiovascular Medicine: Are We There Yet?},
  volume = {104},
  copyright = {\textcopyright{} Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.},
  issn = {1355-6037, 1468-201X},
  shorttitle = {Machine Learning in Cardiovascular Medicine},
  doi = {10.1136/heartjnl-2017-311198},
  abstract = {Artificial intelligence (AI) broadly refers to analytical algorithms that iteratively learn from data, allowing computers to find hidden insights without being explicitly programmed where to look. These include a family of operations encompassing several terms like machine learning, cognitive learning, deep learning and reinforcement learning-based methods that can be used to integrate and interpret complex biomedical and healthcare data in scenarios where traditional statistical methods may not be able to perform. In this review article, we discuss the basics of machine learning algorithms and what potential data sources exist; evaluate the need for machine learning; and examine the potential limitations and challenges of implementing machine in the context of cardiovascular medicine. The most promising avenues for AI in medicine are the development of automated risk prediction algorithms which can be used to guide clinical care; use of unsupervised learning techniques to more precisely phenotype complex disease; and the implementation of reinforcement learning algorithms to intelligently augment healthcare providers. The utility of a machine learning-based predictive model will depend on factors including data heterogeneity, data depth, data breadth, nature of modelling task, choice of machine learning and feature selection algorithms, and orthogonal evidence. A critical understanding of the strength and limitations of various methods and tasks amenable to machine learning is vital. By leveraging the growing corpus of big data in medicine, we detail pathways by which machine learning may facilitate optimal development of patient-specific models for improving diagnoses, intervention and outcome in cardiovascular medicine.},
  language = {en},
  number = {14},
  journal = {Heart},
  author = {Shameer, Khader and Johnson, Kipp W. and Glicksberg, Benjamin S. and Dudley, Joel T. and Sengupta, Partho P.},
  month = jul,
  year = {2018},
  keywords = {heart disease},
  pages = {1156-1164},
  pmid = {29352006}
}

@article{Jiang:2015:emerging,
  title = {The Emerging Roles of Long Noncoding {{RNAs}} in Common Cardiovascular Diseases},
  volume = {38},
  copyright = {2015 Nature Publishing Group},
  issn = {1348-4214},
  doi = {10.1038/hr.2015.26},
  abstract = {Long noncoding RNAs (lncRNAs) are defined as noncoding RNAs that are longer than \textasciitilde{}200 nucleotides and lack protein-encoding capacity. It has been shown that lncRNAs are involved in multiple human diseases by regulating gene expression at various levels. However, studies of lncRNAs in the cardiovascular system are still in their infancy. A growing body of evidence suggests that lncRNAs are also involved in common cardiovascular diseases, including cardiac development, atherosclerosis, myocardial infarction, heart failure, hypertension and aneurysms. In this review, we summarize the current understanding of lncRNAs in common cardiovascular diseases in an effort to better elucidate the molecular mechanism of cardiovascular diseases and provide a basis for exploring new therapeutic targets in those diseases.},
  language = {en},
  number = {6},
  journal = {Hypertension Research},
  author = {Jiang, Xiaoying and Ning, Qilan},
  month = jun,
  year = {2015},
  pages = {375-379}
}

@article{Uchida:2015:Long,
  title = {Long {{Noncoding RNAs}} in {{Cardiovascular Diseases}}},
  volume = {116},
  issn = {0009-7330, 1524-4571},
  doi = {10.1161/CIRCRESAHA.116.302521},
  language = {en},
  number = {4},
  journal = {Circulation Research},
  author = {Uchida, S. and Dimmeler, S.},
  month = feb,
  year = {2015},
  pages = {737-750}
}

@article{Joyner:2011:Ten,
  title = {Ten Questions about Systems Biology},
  volume = {589},
  copyright = {\textcopyright{} 2011 The Authors. Journal compilation \textcopyright{} 2011 The Physiological Society},
  issn = {1469-7793},
  doi = {10.1113/jphysiol.2010.201509},
  abstract = {In this paper we raise `ten questions' broadly related to `omics', the term systems biology, and why the new biology has failed to deliver major therapeutic advances for many common diseases, especially diabetes and cardiovascular disease. We argue that a fundamentally narrow and reductionist perspective about the contribution of genes and genetic variants to disease is a key reason `omics' has failed to deliver the anticipated breakthroughs. We then point out the critical utility of key concepts from physiology like homeostasis, regulated systems and redundancy as major intellectual tools to understand how whole animals adapt to the real world. We argue that a lack of fluency in these concepts is a major stumbling block for what has been narrowly defined as `systems biology' by some of its leading advocates. We also point out that it is a failure of regulation at multiple levels that causes many common diseases. Finally, we attempt to integrate our critique of reductionism into a broader social framework about so-called translational research in specific and the root causes of common diseases in general. Throughout we offer ideas and suggestions that might be incorporated into the current biomedical environment to advance the understanding of disease through the perspective of physiology in conjunction with epidemiology as opposed to bottom-up reductionism alone.},
  language = {en},
  number = {5},
  journal = {The Journal of Physiology},
  author = {Joyner, Michael J. and Pedersen, Bente K.},
  month = mar,
  year = {2011},
  pages = {1017-1030},
  annote = {Convincing arguments in favor of integrative physiology (in contrast with systems biology) through thought-provoking questions. Two major criticized things about "omics", or systems biology, are (1) the fact that holistic consideration of living system has long been a foundation of integrative physiology, part of 'traditional biology" but seems to be dis-regarded by reductionist approaches in molecular genetics, and (2) that the hypothesis-neutral approach is not as fruitful as hypothesis-driven studies. Although the cases for (2) are not rigorously cited or demonstrated in the article, there are citations that worth further investigation:

* Pereira \& Weinshilboum 2009; Schroth et al. 2009, for the better outcome of pharmacogenetics thanks to their directed focus on hypothesis-driven studies

* Gibson 2007; Enattah et al. 2008; Ingram et al. 2009, Simonson et al. 2010; Yi et al. 2010, for fruitful research of anthropology seeking answers for specific questions on lactase persistence and genetic adaptations to extreme altitude.}
}

@article{Lee:2011:Database,
  title = {A {{Database}} of {{Gene}}-{{Environment Interactions Pertaining}} to {{Blood Lipid Traits}}, {{Cardiovascular Disease}} and {{Type}} 2 {{Diabetes}}},
  volume = {2},
  issn = {2153-0602},
  doi = {10.4172/2153-0602.1000106},
  abstract = {As the role of the environment \textendash{} diet, exercise, alcohol and tobacco use and sleep among others \textendash{} is accorded a more prominent role in modifying the relationship between genetic variants and clinical measures of disease, consideration of gene-environment (GxE) interactions is a must. To facilitate incorporation of GxE interactions into single-gene and genome-wide association studies, we have compiled from the literature a database of GxE interactions relevant to nutrition, blood lipids, cardiovascular disease and type 2 diabetes. Over 550 such interactions have been incorporated into a single database, along with over 1430 instances where a lack of statistical significance was found. This database will serve as an important resource to researchers in genetics and nutrition in order to gain an understanding of which points in the human genome are sensitive to variations in diet, physical activity and alcohol use, among other lifestyle choices. Furthermore, this GxE database has been designed with future integration into a larger database of nutritional phenotypes in mind.},
  number = {1},
  journal = {Journal of data mining in genomics \& proteomics},
  author = {Lee, Yu-Chi and Lai, Chao-Qiang and Ordovas, Jose M and Parnell, Laurence D},
  month = jan,
  year = {2011},
  pmid = {22328972},
  pmcid = {PMC3275815}
}

@article{Lopes:2013:Genetic,
  title = {Genetic Complexity in Hypertrophic Cardiomyopathy Revealed by High-Throughput Sequencing},
  volume = {50},
  copyright = {Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/3.0/ and http://creativecommons.org/licenses/by-nc/3.0/legalcode},
  issn = {0022-2593, 1468-6244},
  doi = {10.1136/jmedgenet-2012-101270},
  abstract = {Background Clinical interpretation of the large number of rare variants identified by high throughput sequencing (HTS) technologies is challenging. The aim of this study was to explore the clinical implications of a HTS strategy for patients with hypertrophic cardiomyopathy (HCM) using a targeted HTS methodology and workflow developed for patients with a range of inherited cardiovascular diseases. By comparing the sequencing results with published findings and with sequence data from a large-scale exome sequencing screen of UK individuals, we sought to quantify the strength of the evidence supporting causality for detected candidate variants.
Methods and results 223 unrelated patients with HCM (46$\pm$15 years at diagnosis, 74\% males) were studied. In order to analyse coding, intronic and regulatory regions of 41 cardiovascular genes, we used solution-based sequence capture followed by massive parallel resequencing on Illumina GAIIx. Average read-depth in the 2.1 Mb target region was 120. Rare (frequency$<$0.5\%) non-synonymous, loss-of-function and splice-site variants were defined as candidates. Excluding titin, we identified 152 distinct candidate variants in sarcomeric or associated genes (89 novel) in 143 patients (64\%). Four sarcomeric genes (MYH7, MYBPC3, TNNI3, TNNT2) showed an excess of rare single non-synonymous single-nucleotide polymorphisms (nsSNPs) in cases compared to controls. The estimated probability that a nsSNP in these genes is pathogenic varied between 57\% and near certainty depending on the location. We detected an additional 94 candidate variants (73 novel) in desmosomal, and ion-channel genes in 96 patients (43\%).
Conclusions This study provides the first large-scale quantitative analysis of the prevalence of sarcomere protein gene variants in patients with HCM using HTS technology. Inclusion of other genes implicated in inherited cardiac disease identifies a large number of non-synonymous rare variants of unknown clinical significance.},
  language = {en},
  number = {4},
  journal = {Journal of Medical Genetics},
  author = {Lopes, Luis R. and Zekavati, Anna and Syrris, Petros and Hubank, Mike and Giambartolomei, Claudia and Dalageorgou, Chrysoula and Jenkins, Sharon and McKenna, William and Consortium, Uk10k Consortium and Plagnol, Vincent and Elliott, Perry M.},
  month = apr,
  year = {2013},
  keywords = {High-throughput sequencing,Genetics,Hypertrophic Cardiomyopathy},
  pages = {228-239},
  pmid = {23396983}
}

@article{Xiao:2014:Multitissue,
  title = {Multi-Tissue {{Analysis}} of {{Co}}-Expression {{Networks}} by {{Higher}}-{{Order Generalized Singular Value Decomposition Identifies Functionally Coherent Transcriptional Modules}}},
  volume = {10},
  issn = {1553-7404},
  doi = {10.1371/journal.pgen.1004006},
  abstract = {Recent high-throughput efforts such as ENCODE have generated a large body of genome-scale transcriptional data in multiple conditions (e.g., cell-types and disease states). Leveraging these data is especially important for network-based approaches to human disease, for instance to identify coherent transcriptional modules (subnetworks) that can inform functional disease mechanisms and pathological pathways. Yet, genome-scale network analysis across conditions is significantly hampered by the paucity of robust and computationally-efficient methods. Building on the Higher-Order Generalized Singular Value Decomposition, we introduce a new algorithmic approach for efficient, parameter-free and reproducible identification of network-modules simultaneously across multiple conditions. Our method can accommodate weighted (and unweighted) networks of any size and can similarly use co-expression or raw gene expression input data, without hinging upon the definition and stability of the correlation used to assess gene co-expression. In simulation studies, we demonstrated distinctive advantages of our method over existing methods, which was able to recover accurately both common and condition-specific network-modules without entailing ad-hoc input parameters as required by other approaches. We applied our method to genome-scale and multi-tissue transcriptomic datasets from rats (microarray-based) and humans (mRNA-sequencing-based) and identified several common and tissue-specific subnetworks with functional significance, which were not detected by other methods. In humans we recapitulated the crosstalk between cell-cycle progression and cell-extracellular matrix interactions processes in ventricular zones during neocortex expansion and further, we uncovered pathways related to development of later cognitive functions in the cortical plate of the developing brain which were previously unappreciated. Analyses of seven rat tissues identified a multi-tissue subnetwork of co-expressed heat shock protein (Hsp) and cardiomyopathy genes (Bag3, Cryab, Kras, Emd, Plec), which was significantly replicated using separate failing heart and liver gene expression datasets in humans, thus revealing a conserved functional role for Hsp genes in cardiovascular disease.},
  language = {en},
  number = {1},
  journal = {PLOS Genetics},
  author = {Xiao, Xiaolin and {Moreno-Moral}, Aida and Rotival, Maxime and Bottolo, Leonardo and Petretto, Enrico},
  month = jan,
  year = {2014},
  keywords = {Algorithms,Genetic networks,Protein interaction networks,Gene expression,Heart,Cardiomyopathies,Neocortex,Network analysis},
  pages = {e1004006}
}

@article{Wilsdon:2017:Recent,
  title = {Recent Advances in Congenital Heart Disease Genomics},
  volume = {6},
  issn = {2046-1402},
  doi = {10.12688/f1000research.10113.1},
  language = {en},
  journal = {F1000Research},
  author = {Wilsdon, Anna and Sifrim, Alejandro and Hitz, Marc-Phillip and Hurles, Matthew and Brook, J. David},
  month = jun,
  year = {2017},
  pages = {869}
}

@article{Landis:2016:Current,
  title = {The {{Current Landscape}} of {{Genetic Testing}} in {{Cardiovascular Malformations}}: {{Opportunities}} and {{Challenges}}},
  volume = {3},
  issn = {2297-055X},
  shorttitle = {The {{Current Landscape}} of {{Genetic Testing}} in {{Cardiovascular Malformations}}},
  doi = {10.3389/fcvm.2016.00022},
  abstract = {Human cardiovascular malformations (CVMs) frequently have a genetic contribution. Through the application of novel technologies such as next generation sequencing, DNA sequence variants associated with CVMs are being identified at a rapid pace. While clinicians are now able to offer testing with next generation sequencing gene panels or whole exome sequencing to any patient with a CVM, the interpretation of genetic variation remains problematic. Variable phenotypic expression, reduced penetrance, inconsistent phenotyping methods, and the lack of high throughput functional testing of variants, contribute to these challenges. This article elaborates critical issues that impact the decision to broadly implement clinical molecular genetic testing in CVMs. Major benefits of testing include establishing a genetic diagnosis, facilitating cost-effective screening of family members who may have subclinical disease, predicting recurrence risk in offspring, enabling early diagnosis and anticipatory management of CV and non-CV disease phenotypes, predicting long term outcomes, and facilitating the development of novel therapies aimed at disease improvement or prevention. Limitations include financial cost, psychosocial cost, and ambiguity of interpretation of results. Multiplex families and patients with syndromic features are two groups where disease causation could potentially be firmly established. However, these account for the minority of the overall CVM population, and there is increasing recognition that genotypes previously associated with syndromes also exist in patients who lack non-CV findings. In all circumstances, ongoing dialogue between cardiologists and clinical geneticists will be needed to accurately interpret genetic testing and improve these patients' health. This may be most effectively implemented by the creation and support of CV genetics services at centers committed to pursuing testing for patients.},
  language = {English},
  journal = {Frontiers in Cardiovascular Medicine},
  author = {Landis, Benjamin J. and Ware, Stephanie M.},
  year = {2016},
  keywords = {Mutation,Genomics,Genetics,congenital heart disease,next generation sequencing,Phenomics,phenotyping}
}

@article{Fischer:2014:Biomarker,
  title = {Biomarker {{Profiling}} by {{Nuclear Magnetic Resonance Spectroscopy}} for the {{Prediction}} of {{All}}-{{Cause Mortality}}: {{An Observational Study}} of 17,345 {{Persons}}},
  volume = {11},
  issn = {1549-1676},
  shorttitle = {Biomarker {{Profiling}} by {{Nuclear Magnetic Resonance Spectroscopy}} for the {{Prediction}} of {{All}}-{{Cause Mortality}}},
  doi = {10.1371/journal.pmed.1001606},
  abstract = {In this study, W\"urtz and colleagues conducted high-throughput profiling of blood specimens in two large population-based cohorts in order to identify biomarkers for all-cause mortality and enhance risk prediction. The authors found that biomarker profiling improved prediction of the short-term risk of death from all causes above established risk factors. However, further investigations are needed to clarify the biological mechanisms and the utility of these biomarkers to guide screening and prevention. Please see later in the article for the Editors' Summary},
  language = {en},
  number = {2},
  journal = {PLOS Medicine},
  author = {Fischer, Krista and Kettunen, Johannes and W\"urtz, Peter and Haller, Toomas and Havulinna, Aki S. and Kangas, Antti J. and Soininen, Pasi and Esko, T\~onu and Tammesoo, Mari-Liis and M\"agi, Reedik and Smit, Steven and Palotie, Aarno and Ripatti, Samuli and Salomaa, Veikko and {Ala-Korpela}, Mika and Perola, Markus and Metspalu, Andres},
  month = feb,
  year = {2014},
  keywords = {Biomarkers,Glycoproteins,Cardiovascular diseases,Absorption spectroscopy,Albumins,Cholesterol,Death rates,NMR spectroscopy},
  pages = {e1001606}
}

@article{Weiss:2012:Good,
  title = {"{{Good Enough Solutions}}" and the {{Genetics}} of {{Complex Diseases}}},
  volume = {111},
  issn = {0009-7330, 1524-4571},
  doi = {10.1161/CIRCRESAHA.112.269084},
  language = {en},
  number = {4},
  journal = {Circulation Research},
  author = {Weiss, J. N. and Karma, A. and MacLellan, W. R. and Deng, M. and Rau, C. D. and Rees, C. M. and Wang, J. and Wisniewski, N. and Eskin, E. and Horvath, S. and Qu, Z. and Wang, Y. and Lusis, A. J.},
  month = aug,
  year = {2012},
  pages = {493-504}
}

@article{Meder:2011:Targeted,
  title = {Targeted {{Next}}-{{Generation Sequencing}} for the {{Molecular Genetic Diagnostics}} of {{Cardiomyopathies}}},
  volume = {4},
  issn = {1942-325X, 1942-3268},
  doi = {10.1161/CIRCGENETICS.110.958322},
  language = {en},
  number = {2},
  journal = {Circulation: Cardiovascular Genetics},
  author = {Meder, B. and Haas, J. and Keller, A. and Heid, C. and Just, S. and Borries, A. and Boisguerin, V. and {Scharfenberger-Schmeer}, M. and Stahler;, P. and Beier, M. and Weichenhan, D. and Strom, T. M. and Pfeufer, A. and Korn, B. and Katus, H. A. and Rottbauer, W.},
  month = apr,
  year = {2011},
  pages = {110-122}
}

@article{Dewey:2016:Distribution,
  title = {Distribution and Clinical Impact of Functional Variants in 50,726 Whole-Exome Sequences from the {{DiscovEHR}} Study},
  volume = {354},
  copyright = {Copyright \textcopyright{} 2016, American Association for the Advancement of Science},
  issn = {0036-8075, 1095-9203},
  doi = {10.1126/science.aaf6814},
  abstract = {Unleashing the power of precision medicine
Precision medicine promises the ability to identify risks and treat patients on the basis of pathogenic genetic variation. Two studies combined exome sequencing results for over 50,000 people with their electronic health records. Dewey et al. found that $\sim$3.5\% of individuals in their cohort had clinically actionable genetic variants. Many of these variants affected blood lipid levels that could influence cardiovascular health. Abul-Husn et al. extended these findings to investigate the genetics and treatment of familial hypercholesterolemia, a risk factor for cardiovascular disease, within their patient pool. Genetic screening helped identify at-risk patients who could benefit from increased treatment.
Science, this issue p. 10.1126/science.aaf6814, p. 10.1126/science.aaf7000
Structured Abstract
INTRODUCTIONLarge-scale genetic studies of integrated health care populations, with phenotypic data captured natively in the documentation of clinical care, have the potential to unveil genetic associations that point the way to new biology and therapeutic targets. This setting also represents an ideal test bed for the implementation of genomics in routine clinical care in service of precision medicine.
RATIONALEThe DiscovEHR collaboration between the Regeneron Genetics Center and Geisinger Health System aims to catalyze genomic discovery and precision medicine by coupling high-throughput exome sequencing to longitudinal electronic health records (EHRs) of participants in Geisinger's MyCode Community Health Initiative. Here, we describe initial insights from whole-exome sequencing of 50,726 adult participants of predominantly European ancestry using clinical phenotypes derived from EHRs.
RESULTSThe median duration of EHR data associated with sequenced participants was 14 years, with a median of 87 clinical encounters, 687 laboratory tests, and seven procedures per participant. Forty-eight percent of sequenced individuals had one or more first- or second-degree relatives in the sample, and genome-wide autozygosity was similar to other outbred European populations. We found \textasciitilde{}4.2 million single-nucleotide variants and insertion/deletion events, of which \textasciitilde{}176,000 are predicted to result in loss of gene function (LoF). The overwhelming majority of these genetic variants occurred at a minor allele frequency of $\leq$1\%, and more than half were singletons. Each participant harbored a median of 21 rare predicted LoFs. At this sample size, \textasciitilde{}92\% of sequenced genes, including genes that encode existing drug targets or confer risk for highly penetrant genetic diseases, harbor rare heterozygous predicted LoF variants. About 7\% of sequenced genes contained rare homozygous predicted LoF variants in at least one individual. Linking these data to EHR-derived laboratory phenotypes revealed consequences of partial or complete LoF in humans. Among these were previously unidentified associations between predicted LoFs in CSF2RB and basophil and eosinophil counts, and EGLN1-associated erythrocytosis segregating in genetically identified family networks. Using predicted LoFs as a model for drug target antagonism, we found associations supporting the majority of therapeutic targets for lipid lowering. To highlight the opportunity for genotype-phenotype association discovery, we performed exome-wide association analyses of EHR-derived lipid values, newly implicating rare predicted LoFs, and deleterious missense variants in G6PC in association with triglyceride levels. In a survey of 76 clinically actionable disease-associated genes, we estimated that 3.5\% of individuals harbor pathogenic or likely pathogenic variants that meet criteria for clinical action. Review of the EHR uncovered findings associated with the monogenic condition in \textasciitilde{}65\% of pathogenic variant carriers' medical records.
CONCLUSIONThe findings reported here demonstrate the value of large-scale sequencing in an integrated health system population, add to the knowledge base regarding the phenotypic consequences of human genetic variation, and illustrate the challenges and promise of genomic medicine implementation. DiscovEHR provides a blueprint for large-scale precision medicine initiatives and genomics-guided therapeutic target discovery. $<$img class="fragment-image" aria-describedby="F1-caption" src="https://d2ufo47lrtsv5s.cloudfront.net/content/sci/354/6319/aaf6814/F1.medium.gif"/$>$ Download high-res image Open in new tab Download Powerpoint Therapeutic target validation and genomic medicine in DiscovEHR.(A) Associations between predicted LoF variants in lipid drug target genes and lipid levels. Boxes correspond to effect size, given as the absolute value of effect, in SD units; whiskers denote 95\% confidence intervals for effect. The size of the box is proportional to the logarithm (base 10) of predicted LoF carriers. (B and C) Prevalence and expressivity of clinically actionable genetic variants in 76 disease genes, according to EHR data. G76, Geisinger-76.
The DiscovEHR collaboration between the Regeneron Genetics Center and Geisinger Health System couples high-throughput sequencing to an integrated health care system using longitudinal electronic health records (EHRs). We sequenced the exomes of 50,726 adult participants in the DiscovEHR study to identify \textasciitilde{}4.2 million rare single-nucleotide variants and insertion/deletion events, of which \textasciitilde{}176,000 are predicted to result in a loss of gene function. Linking these data to EHR-derived clinical phenotypes, we find clinical associations supporting therapeutic targets, including genes encoding drug targets for lipid lowering, and identify previously unidentified rare alleles associated with lipid levels and other blood level traits. About 3.5\% of individuals harbor deleterious variants in 76 clinically actionable genes. The DiscovEHR data set provides a blueprint for large-scale precision medicine initiatives and genomics-guided therapeutic discovery.
More than 50,000 exomes, coupled with electronic health records, inform on medically relevant genetic variants.
More than 50,000 exomes, coupled with electronic health records, inform on medically relevant genetic variants.},
  language = {en},
  number = {6319},
  journal = {Science},
  author = {Dewey, Frederick E. and Murray, Michael F. and Overton, John D. and Habegger, Lukas and Leader, Joseph B. and Fetterolf, Samantha N. and O'Dushlaine, Colm and Hout, Cristopher V. Van and Staples, Jeffrey and {Gonzaga-Jauregui}, Claudia and Metpally, Raghu and Pendergrass, Sarah A. and Giovanni, Monica A. and Kirchner, H. Lester and Balasubramanian, Suganthi and {Abul-Husn}, Noura S. and Hartzel, Dustin N. and Lavage, Daniel R. and Kost, Korey A. and Packer, Jonathan S. and Lopez, Alexander E. and Penn, John and Mukherjee, Semanti and Gosalia, Nehal and Kanagaraj, Manoj and Li, Alexander H. and Mitnaul, Lyndon J. and Adams, Lance J. and Person, Thomas N. and Praveen, Kavita and Marcketta, Anthony and Lebo, Matthew S. and {Austin-Tse}, Christina A. and {Mason-Suares}, Heather M. and Bruse, Shannon and Mellis, Scott and Phillips, Robert and Stahl, Neil and Murphy, Andrew and Economides, Aris and Skelding, Kimberly A. and Still, Christopher D. and Elmore, James R. and Borecki, Ingrid B. and Yancopoulos, George D. and Davis, F. Daniel and Faucett, William A. and Gottesman, Omri and Ritchie, Marylyn D. and Shuldiner, Alan R. and Reid, Jeffrey G. and Ledbetter, David H. and Baras, Aris and Carey, David J.},
  month = dec,
  year = {2016},
  pages = {aaf6814},
  pmid = {28008009}
}

@article{Churko:2013:Overview,
  title = {Overview of {{High Throughput Sequencing Technologies}} to {{Elucidate Molecular Pathways}} in {{Cardiovascular Diseases}}},
  volume = {112},
  issn = {0009-7330, 1524-4571},
  doi = {10.1161/CIRCRESAHA.113.300939},
  language = {en},
  number = {12},
  journal = {Circulation Research},
  author = {Churko, J. M. and Mantalas, G. L. and Snyder, M. P. and Wu, J. C.},
  month = jun,
  year = {2013},
  pages = {1613-1623}
}

@article{Cheek:2003:Genetic,
  title = {Genetic {{Predictors}} of {{Cardiovascular Disease}}: {{The Use}} of {{Chip Technology}}},
  volume = {18},
  issn = {0889-4655},
  shorttitle = {Genetic {{Predictors}} of {{Cardiovascular Disease}}},
  abstract = {Cardiovascular disease, a primary cause of mortality in the United States, has a complex pathologic process involving many genes. The high-throughput technology (microarray or "DNA chip") used to decipher the human genome is now being employed to identify key genes in its development. A study focusing on candidate genes associated with premature cardiovascular disease discovered that missense variations in the thrombospondin 1 and 4 genes were associated with premature coronary artery disease, while a mutation in the non-coding region of a thrombospondin 2 gene imparts protection from developing heart disease. Although the clinical implications of microarray technology are still under investigation, this research may lead to a diagnostic test to determine a patient's risk for developing heart disease.},
  language = {en-US},
  number = {1},
  journal = {Journal of Cardiovascular Nursing},
  author = {Cheek, Dennis J. and Cesan, Annushka},
  month = jan,
  year = {2003},
  pages = {50}
}

@book{Zipes:2019:Braunwald,
  address = {Philadelphia, PA},
  edition = {Eleventh edition, international edition},
  title = {Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine},
  isbn = {978-0-323-46342-3},
  shorttitle = {Braunwald's Heart Disease},
  language = {eng},
  publisher = {{Elsevier}},
  editor = {Zipes, Douglas P. and Libby, Peter and Bonow, Robert O. and Mann, Douglas L. and Tomaselli, Gordon F. and Braunwald, Eugene},
  year = {2019},
  note = {OCLC: 1048373751},
  annote = {[object Object]}
}

@article{:2013:Largescale,
  title = {Large-Scale Association Analysis Identifies New Risk Loci for Coronary Artery Disease},
  volume = {45},
  issn = {1061-4036},
  doi = {10.1038/ng.2480},
  abstract = {Coronary artery disease (CAD) is the commonest cause of death. Here, we report an association analysis in 63,746 CAD cases and 130,681 controls identifying 15 loci reaching genome-wide significance, taking the number of susceptibility loci for CAD to 46, and a further 104 independent variants (r2 $<$ 0.2) strongly associated with CAD at a 5\% false discovery rate (FDR). Together, these variants explain approximately 10.6\% of CAD heritability. Of the 46 genome-wide significant lead SNPs, 12 show a significant association with a lipid trait, and 5 show a significant association with blood pressure, but none is significantly associated with diabetes. Network analysis with 233 candidate genes (loci at 10\% FDR) generated 5 interaction networks comprising 85\% of these putative genes involved in CAD. The four most significant pathways mapping to these networks are linked to lipid metabolism and inflammation, underscoring the causal role of these activities in the genetic etiology of CAD. Our study provides insights into the genetic basis of CAD and identifies key biological pathways.},
  number = {1},
  journal = {Nature genetics},
  month = jan,
  year = {2013},
  pages = {25-33},
  pmid = {23202125},
  pmcid = {PMC3679547},
  annote = {Cited in Braunwald's heart disease - Chapter 7, for construction of a genetic risk score for Coronary Artery Disease or Myocardial Infarction using 45 mapped variants.}
}

@incollection{Musunuru:2019:Principles,
  address = {Philadelphia, PA},
  edition = {11},
  title = {Principles of {{Cardiovascular Genetics}}},
  booktitle = {Braunwald's {{Heart Disease}}: {{A Textbook}} of {{Cardiovascular Medicine}}},
  publisher = {{Elsevier}},
  author = {Musunuru, Kiran and Kathiresan, Sekar},
  year = {2019},
  pages = {53-63},
  annote = {Study designs to correlate genotype vs phenotype

1. Family-based studies: appropriate for monogenic disorders. 2 types: classical linkage studies and exome sequencing

2. Extreme-phenotype studies

3. Population-based studies, especially for polygenic disorders. Most common type is GWAS.

~}
}

@article{Burke:2016:Clinical,
  title = {Clinical and {{Mechanistic Insights Into}} the~{{Genetics}} of {{Cardiomyopathy}}},
  volume = {68},
  issn = {0735-1097},
  doi = {10.1016/j.jacc.2016.08.079},
  abstract = {Over the last quarter-century, there has been tremendous progress in genetics research that has defined molecular causes for cardiomyopathies. More than a thousand mutations have been identified in many genes with varying ontologies, therein indicating the diverse molecules and pathways that cause hypertrophic, dilated, restrictive, and arrhythmogenic cardiomyopathies. Translation of this research to the clinic via genetic testing can precisely group affected patients according to molecular etiology, and identify individuals without evidence of disease who are at high risk for developing cardiomyopathy. These advances provide insights into the earliest manifestations of cardiomyopathy and help to define the molecular pathophysiological basis for cardiac remodeling. Although these efforts remain incomplete, new genomic technologies and analytic strategies provide unparalleled opportunities to fully explore the genetic architecture of cardiomyopathies. Such data hold the promise that mutation-specific pathophysiology will uncover novel therapeutic targets, and herald the beginning of precision therapy for cardiomyopathy patients.},
  number = {25},
  journal = {Journal of the American College of Cardiology},
  author = {Burke, Michael A. and Cook, Stuart A. and Seidman, Jonathan G. and Seidman, Christine E.},
  month = dec,
  year = {2016},
  keywords = {genetics,dilated cardiomyopathy,genetic testing,hypertrophic cardiomyopathy,molecular etiology,restrictive cardiomyopathy},
  pages = {2871-2886}
}

@article{Eichler:2010:Missing,
  title = {Missing Heritability and Strategies for Finding the Underlying Causes of Complex Disease},
  volume = {11},
  copyright = {2010 Nature Publishing Group},
  issn = {1471-0064},
  doi = {10.1038/nrg2809},
  abstract = {Although recent genome-wide studies have provided valuable insights into the genetic basis of human disease, they have explained relatively little of the heritability of most complex traits, and the variants identified through these studies have small effect sizes. This has led to the important and hotly debated issue of where the 'missing heritability' of complex diseases might be found. Here, seven leading geneticists offer their opinion about where this heritability is likely to lie, what this could tell us about the underlying genetic architecture of common diseases and how this could inform research strategies for uncovering genetic risk factors.},
  language = {en},
  number = {6},
  journal = {Nature Reviews Genetics},
  author = {Eichler, Evan E. and Flint, Jonathan and Gibson, Greg and Kong, Augustine and Leal, Suzanne M. and Moore, Jason H. and Nadeau, Joseph H.},
  month = jun,
  year = {2010},
  pages = {446-450}
}

@incollection{Macrae:2019:Personalized,
  address = {Philadelphia, PA},
  edition = {11},
  title = {Personalized and {{Precision Cardiovascular Medicine}}},
  booktitle = {Braunwald's {{Heart Disease}}: {{A Textbook}} of {{Cardiovascular Medicine}}},
  publisher = {{Elsevier}},
  author = {Macrae, Calum A.},
  year = {2019},
  pages = {47-52},
  annote = {Layers of data

Despite some remarkable insights from functional genomics, the incorporation of new profiling technologies into the clinical arena has been slow, largely because of appropriate concerns regarding the need for robust validation through prospective approaches. It is difficult to see how traditional study designs can be appropriately scaled. Full exploitation of these approaches will require building investigative platforms that allow the study of integrative biology in large populations and in multiple different disease states.

~}
}

@article{Vasli:2012:Next,
  title = {Next Generation Sequencing for Molecular Diagnosis of Neuromuscular Diseases},
  volume = {124},
  issn = {0001-6322, 1432-0533},
  doi = {10.1007/s00401-012-0982-8},
  abstract = {Inherited neuromuscular disorders (NMD) are chronic genetic diseases posing a significant burden on patients and the health care system. Despite tremendous research and clinical efforts, the molecular causes remain unknown for nearly half of the patients, due to genetic heterogeneity and conventional molecular diagnosis based on a gene-by-gene approach. We aimed to test next generation sequencing (NGS) as an efficient and cost-effective strategy to accelerate patient diagnosis. We designed a capture library to target the coding and splice site sequences of all known NMD genes and used NGS and DNA multiplexing to retrieve the pathogenic mutations in patients with heterogeneous NMD with or without known mutations. We retrieved all known mutations, including point mutations and small indels, intronic and exonic mutations, and a large deletion in a patient with Duchenne muscular dystrophy, validating the sensitivity and reproducibility of this strategy on a heterogeneous subset of NMD with different genetic inheritance. Most pathogenic mutations were ranked on top in our blind bioinformatic pipeline. Following the same strategy, we characterized probable TTN, RYR1 and COL6A3 mutations in several patients without previous molecular diagnosis. The cost was less than conventional testing for a single large gene. With appropriate adaptations, this strategy could be implemented into a routine genetic diagnosis set-up as a first screening approach to detect most kind of mutations, potentially before the need of more invasive and specific clinical investigations. An earlier genetic diagnosis should provide improved disease management and higher quality genetic counseling, and ease access to therapy or inclusion into therapeutic trials.},
  language = {en},
  number = {2},
  journal = {Acta Neuropathologica},
  author = {Vasli, Nasim and B\"ohm, Johann and Gras, St\'ephanie Le and Muller, Jean and Pizot, C\'ecile and Jost, Bernard and {Echaniz-Laguna}, Andoni and Laugel, Vincent and Tranchant, Christine and Bernard, Rafaelle and Plewniak, Fr\'ed\'eric and Vicaire, Serge and Levy, Nicolas and Chelly, Jamel and Mandel, Jean-Louis and Biancalana, Val\'erie and Laporte, Jocelyn},
  month = aug,
  year = {2012},
  pages = {273-283}
}

@article{Rehm:2015:ClinGen,
  title = {{{ClinGen}} \textemdash{} {{The Clinical Genome Resource}}},
  volume = {372},
  issn = {0028-4793, 1533-4406},
  doi = {10.1056/NEJMsr1406261},
  language = {en},
  number = {23},
  journal = {New England Journal of Medicine},
  author = {Rehm, Heidi L. and Berg, Jonathan S. and Brooks, Lisa D. and Bustamante, Carlos D. and Evans, James P. and Landrum, Melissa J. and Ledbetter, David H. and Maglott, Donna R. and Martin, Christa Lese and Nussbaum, Robert L. and Plon, Sharon E. and Ramos, Erin M. and Sherry, Stephen T. and Watson, Michael S.},
  month = jun,
  year = {2015},
  pages = {2235-2242},
  annote = {various commercial and academic entities maintain isolated, sometimes proprietary, databases of variant interpretations, thus preventing the sharing of critical knowledge that could benefit patients, families, health care providers, diagnostic laboratories, and payers.}
}

@article{Manrai:2016:Clinical,
  title = {Clinical {{Genomics}}: {{From Pathogenicity Claims}} to {{Quantitative Risk Estimates}}},
  volume = {315},
  issn = {0098-7484},
  shorttitle = {Clinical {{Genomics}}},
  doi = {10.1001/jama.2016.1519},
  language = {en},
  number = {12},
  journal = {JAMA},
  author = {Manrai, Arjun K. and Ioannidis, John P. A. and Kohane, Isaac S.},
  month = mar,
  year = {2016},
  pages = {1233},
  annote = {Clearly written commentary about why precision medicine is necessary. Rigorously cited sources about pathogenic variants later found to be non-pathogenic.}
}

@article{Meilhac:2014:Cardiac,
  title = {Cardiac {{Cell Lineages}} That {{Form}} the {{Heart}}},
  volume = {4},
  issn = {, 2157-1422},
  doi = {10.1101/cshperspect.a013888},
  abstract = {Myocardial cells ensure the contractility of the heart, which also depends on other mesodermal cell types for its function. Embryological experiments had identified the sources of cardiac precursor cells. With the advent of genetic engineering, novel tools have been used to reconstruct the lineage tree of cardiac cells that contribute to different parts of the heart, map the development of cardiac regions, and characterize their genetic signature. Such knowledge is of fundamental importance for our understanding of cardiogenesis and also for the diagnosis and treatment of heart malformations.},
  language = {en},
  number = {9},
  journal = {Cold Spring Harbor Perspectives in Medicine},
  author = {Meilhac, Sigol\`ene M. and Lescroart, Fabienne and Blanpain, C\'edric and Buckingham, Margaret E.},
  month = jan,
  year = {2014},
  pages = {a013888},
  pmid = {25183852}
}

@article{Lian:2014:NextGeneration,
  title = {Next-{{Generation Models}} of {{Human Cardiogenesis}} via {{Genome Editing}}},
  volume = {4},
  issn = {, 2157-1422},
  doi = {10.1101/cshperspect.a013920},
  abstract = {Cardiogenesis is one of the earliest and most important steps during human development and is orchestrated by discrete families of heart progenitors, which build distinct regions of the fetal heart. For the past decade, a lineage map for the distinct subsets of progenitors that generate the embryonic mammalian heart has begun to lay a foundation for the development of new strategies for rebuilding the adult heart after injury, an unmet clinical need for the vast majority of patients with end-stage heart failure who are not heart transplant recipients. The studies also have implications for the root causes of congenital heart disease, which affects 1 in 50 live births, the most prevalent malformations in children. Although much of this insight has been generated in murine models, it is becoming increasingly clear that there can be important divergence with principles and pathways for human cardiogenesis, as well as for regenerative pathways. The development of human stem cell models, coupled with recent advances in genome editing with RNA-guided endonucleases, offers a new approach for the primary study of human cardiogenesis. In addition, application of the technology to the in vivo setting in large animal models, including nonhuman primates, has opened the door to genome-edited large animal models of adult and congenital heart disease, as well as a detailed mechanistic dissection of the more diverse and complex set of progenitor families and pathways, which guide human cardiogenesis. Implications of this new technology for a new generation of human-based, genetically tractable systems are discussed, along with potential therapeutic applications.},
  language = {en},
  number = {12},
  journal = {Cold Spring Harbor Perspectives in Medicine},
  author = {Lian, Xiaojun and Xu, Jiejia and Li, Jinsong and Chien, Kenneth R.},
  month = jan,
  year = {2014},
  pages = {a013920},
  pmid = {25237142}
}

@article{Waardenberg:2014:Genetic,
  title = {Genetic {{Networks Governing Heart Development}}},
  volume = {4},
  issn = {, 2157-1422},
  doi = {10.1101/cshperspect.a013839},
  abstract = {Animal genomes contain a code for construction of the body plan from a fertilized egg. Understanding how genome information is deciphered to create the complex multilayered regulatory systems that drive organismal development, and which become altered in disease, is one of the greatest challenges in the biological sciences. The development of methods that effectively represent and communicate the complexity inherent in gene regulatory networks remains a major barrier. This review introduces the philosophy of systems biology and discusses recent progress in understanding the development of the heart at a systems biology level.},
  language = {en},
  number = {11},
  journal = {Cold Spring Harbor Perspectives in Medicine},
  author = {Waardenberg, Ashley J. and Ramialison, Mirana and Bouveret, Romaric and Harvey, Richard P.},
  month = jan,
  year = {2014},
  pages = {a013839},
  pmid = {25280899}
}

@article{Novakovic:2014:Myocardial,
  title = {Myocardial {{Tissue Engineering}}: {{In Vitro Models}}},
  volume = {4},
  issn = {, 2157-1422},
  shorttitle = {Myocardial {{Tissue Engineering}}},
  doi = {10.1101/cshperspect.a014076},
  abstract = {Modeling integrated human physiology in vitro is a formidable task not yet achieved with any of the existing cell/tissue systems. However, tissue engineering is becoming increasingly successful at authentic representation of the actual environmental milieu of tissue development, regeneration and disease progression, and in providing real-time insights into morphogenic events. Functional human tissue units engineered to combine biological fidelity with the high-throughput screening and real-time measurement of physiological responses are poised to transform drug screening and predictive modeling of disease. In this review, we focus on the in vitro engineering of functional human myocardium that mimics heart tissue for analysis of myocardial function, in the context of physiological studies, drug screening for therapeutics, and safety pharmacology.},
  language = {en},
  number = {3},
  journal = {Cold Spring Harbor Perspectives in Medicine},
  author = {Novakovic, Gordana Vunjak and Eschenhagen, Thomas and Mummery, Christine},
  month = jan,
  year = {2014},
  pages = {a014076},
  pmid = {24591534}
}

@article{Musunuru:2015:Personalized,
  title = {Personalized {{Genomes}} and {{Cardiovascular Disease}}},
  volume = {5},
  issn = {, 2157-1422},
  doi = {10.1101/cshperspect.a014068},
  abstract = {The emerging ability to obtain a personalized genome, that is, to perform whole-genome sequencing to determine the entirety of the DNA sequence in an individual patient's chromosomes, holds out the promise of transforming patient care by allowing physicians to more accurately predict the risk of disease and to tailor therapy to that individual. Although no established applications of personalized genomics in cardiovascular medicine yet exist, there are at least two emerging applications that may ultimately become everyday practice. In the first application, DNA sequence variants that have been found to be associated with cardiovascular disease may be incorporated in risk-prediction algorithms to more accurately forecast whether patients will develop disease. In the second application, known as pharmacogenomics, DNA sequence variants that have been found to be associated with either beneficial effects or adverse effects of a medication may be used to help decide which medications or dosages of medications to prescribe to patients. It remains to be seen whether either of these applications will prove to be both cost effective as well as of clinical benefit.},
  language = {en},
  number = {1},
  journal = {Cold Spring Harbor Perspectives in Medicine},
  author = {Musunuru, Kiran},
  month = jan,
  year = {2015},
  pages = {a014068},
  pmid = {25256177}
}

@article{Berg:2013:informatics,
  title = {An Informatics Approach to Analyzing the Incidentalome},
  volume = {15},
  issn = {1098-3600},
  doi = {10.1038/gim.2012.112},
  abstract = {Purpose: Next-generation sequencing has transformed genetic research and is poised to revolutionize clinical diagnosis. However, the vast amount of data and inevitable discovery of incidental findings require novel analytic approaches. We therefore implemented for the first time a strategy that utilizes an a priori structured framework and a conservative threshold for selecting clinically relevant incidental findings. Methods: We categorized 2,016 genes linked with Mendelian diseases into "bins" based on clinical utility and validity and used a computational algorithm to analyze 80 whole-genome sequences in order to explore the use of such an approach in a simulated real-world setting. Results: The algorithm effectively reduced the number of variants requiring human review and identified incidental variants with likely clinical relevance. Incorporation of the Human Gene Mutation Database improved the yield for missense mutations but also revealed that a substantial proportion of purported disease-causing mutations were misleading. Conclusion: This approach is adaptable to any clinically relevant bin structure, scalable to the demands of a clinical laboratory work-flow, and flexible with respect to advances in genomics. We anticipate that application of this strategy will facilitate pretest informed consent, laboratory analysis, and posttest return of results in a clinical context. Genet Med 2013:15(1):36-44},
  language = {English},
  number = {1},
  journal = {Genetics in Medicine},
  author = {Berg, Jonathan S. and Adams, Michael and Nassar, Nassib and Bizon, Chris and Lee, Kristy and Schmitt, Charles P. and Wilhelmsen, Kirk C. and Evans, James P.},
  month = jan,
  year = {2013},
  keywords = {medicine,clinical informatics,disease,incidental findings,personal genome,secondary findings,substitutions,variants,whole-exome sequencing,whole-genome sequencing},
  pages = {36-44},
  note = {WOS:000313460900004}
}

@article{Kohler:2017:Human,
  title = {The {{Human Phenotype Ontology}} in 2017},
  volume = {45},
  issn = {0305-1048},
  doi = {10.1093/nar/gkw1039},
  abstract = {Deep phenotyping has been defined as the precise and comprehensive analysis of phenotypic abnormalities in which the individual components of the phenotype are observed and described. The three components of the Human Phenotype Ontology (HPO; www.human-phenotype-ontology.org) project are the phenotype vocabulary, disease-phenotype annotations and the algorithms that operate on these. These components are being used for computational deep phenotyping and precision medicine as well as integration of clinical data into translational research. The HPO is being increasingly adopted as a standard for phenotypic abnormalities by diverse groups such as international rare disease organizations, registries, clinical labs, biomedical resources, and clinical software tools and will thereby contribute toward nascent efforts at global data exchange for identifying disease etiologies. This update article reviews the progress of the HPO project since the debut Nucleic Acids Research database article in 2014, including specific areas of expansion such as common (complex) disease, new algorithms for phenotype driven genomic discovery and diagnostics, integration of cross-species mapping efforts with the Mammalian Phenotype Ontology, an improved quality control pipeline, and the addition of patient-friendly terminology.},
  number = {Database issue},
  journal = {Nucleic Acids Research},
  author = {K\"ohler, Sebastian and Vasilevsky, Nicole A. and Engelstad, Mark and Foster, Erin and McMurry, Julie and Aym\'e, S\'egol\`ene and Baynam, Gareth and Bello, Susan M. and Boerkoel, Cornelius F. and Boycott, Kym M. and Brudno, Michael and Buske, Orion J. and Chinnery, Patrick F. and Cipriani, Valentina and Connell, Laureen E. and Dawkins, Hugh J.S. and DeMare, Laura E. and Devereau, Andrew D. and {de Vries}, Bert B.A. and Firth, Helen V. and Freson, Kathleen and Greene, Daniel and Hamosh, Ada and Helbig, Ingo and Hum, Courtney and J\"ahn, Johanna A. and James, Roger and Krause, Roland and F. Laulederkind, Stanley J. and Lochm\"uller, Hanns and Lyon, Gholson J. and Ogishima, Soichi and Olry, Annie and Ouwehand, Willem H. and Pontikos, Nikolas and Rath, Ana and Schaefer, Franz and Scott, Richard H. and Segal, Michael and Sergouniotis, Panagiotis I. and Sever, Richard and Smith, Cynthia L. and Straub, Volker and Thompson, Rachel and Turner, Catherine and Turro, Ernest and Veltman, Marijcke W.M. and Vulliamy, Tom and Yu, Jing and {von Ziegenweidt}, Julie and Zankl, Andreas and Z\"uchner, Stephan and Zemojtel, Tomasz and Jacobsen, Julius O.B. and Groza, Tudor and Smedley, Damian and Mungall, Christopher J. and Haendel, Melissa and Robinson, Peter N.},
  month = jan,
  year = {2017},
  pages = {D865-D876},
  pmid = {27899602},
  pmcid = {PMC5210535},
  annote = {Go through Table 1 (list of clinical databases) and check out these databases.}
}

@article{Kohler:2014:Human,
  title = {The {{Human Phenotype Ontology}} Project: Linking Molecular Biology and Disease through Phenotype Data},
  volume = {42},
  issn = {0305-1048},
  shorttitle = {The {{Human Phenotype Ontology}} Project},
  doi = {10.1093/nar/gkt1026},
  abstract = {Abstract.  The Human Phenotype Ontology (HPO) project, available at http://www.human-phenotype-ontology.org, provides a structured, comprehensive and well-defin},
  language = {en},
  number = {D1},
  journal = {Nucleic Acids Research},
  author = {K\"ohler, Sebastian and Doelken, Sandra C. and Mungall, Christopher J. and Bauer, Sebastian and Firth, Helen V. and {Bailleul-Forestier}, Isabelle and Black, Graeme C. M. and Brown, Danielle L. and Brudno, Michael and Campbell, Jennifer and FitzPatrick, David R. and Eppig, Janan T. and Jackson, Andrew P. and Freson, Kathleen and Girdea, Marta and Helbig, Ingo and Hurst, Jane A. and J\"ahn, Johanna and Jackson, Laird G. and Kelly, Anne M. and Ledbetter, David H. and Mansour, Sahar and Martin, Christa L. and Moss, Celia and Mumford, Andrew and Ouwehand, Willem H. and Park, Soo-Mi and Riggs, Erin Rooney and Scott, Richard H. and Sisodiya, Sanjay and Vooren, Steven Van and Wapner, Ronald J. and Wilkie, Andrew O. M. and Wright, Caroline F. and Silfhout, Vulto-van and T, Anneke and de Leeuw, Nicole and Vries, De and A, Bert B. and Washingthon, Nicole L. and Smith, Cynthia L. and Westerfield, Monte and Schofield, Paul and Ruef, Barbara J. and Gkoutos, Georgios V. and Haendel, Melissa and Smedley, Damian and Lewis, Suzanna E. and Robinson, Peter N.},
  month = jan,
  year = {2014},
  pages = {D966-D974}
}

@article{Consortium:2015:Integrative,
  title = {Integrative Analysis of 111 Reference Human Epigenomes},
  volume = {518},
  copyright = {2015 Nature Publishing Group},
  issn = {1476-4687},
  doi = {10.1038/nature14248},
  abstract = {The reference human genome sequence set the stage for studies of genetic variation and its association with human disease, but epigenomic studies lack a similar reference. To address this need, the NIH Roadmap Epigenomics Consortium generated the largest collection so far of human epigenomes for primary cells and tissues. Here we describe the integrative analysis of 111 reference human epigenomes generated as part of the programme, profiled for histone modification patterns, DNA accessibility, DNA methylation and RNA expression. We establish global maps of regulatory elements, define regulatory modules of coordinated activity, and their likely activators and repressors. We show that disease- and trait-associated genetic variants are enriched in tissue-specific epigenomic marks, revealing biologically relevant cell types for diverse human traits, and providing a resource for interpreting the molecular basis of human disease. Our results demonstrate the central role of epigenomic information for understanding gene regulation, cellular differentiation and human disease.},
  language = {en},
  number = {7539},
  journal = {Nature},
  author = {Consortium, Roadmap Epigenomics and Kundaje, Anshul and Meuleman, Wouter and Ernst, Jason and Bilenky, Misha and Yen, Angela and {Heravi-Moussavi}, Alireza and Kheradpour, Pouya and Zhang, Zhizhuo and Wang, Jianrong and Ziller, Michael J. and Amin, Viren and Whitaker, John W. and Schultz, Matthew D. and Ward, Lucas D. and Sarkar, Abhishek and Quon, Gerald and Sandstrom, Richard S. and Eaton, Matthew L. and Wu, Yi-Chieh and Pfenning, Andreas R. and Wang, Xinchen and Claussnitzer, Melina and Liu, Yaping and Coarfa, Cristian and Harris, R. Alan and Shoresh, Noam and Epstein, Charles B. and Gjoneska, Elizabeta and Leung, Danny and Xie, Wei and Hawkins, R. David and Lister, Ryan and Hong, Chibo and Gascard, Philippe and Mungall, Andrew J. and Moore, Richard and Chuah, Eric and Tam, Angela and Canfield, Theresa K. and Hansen, R. Scott and Kaul, Rajinder and Sabo, Peter J. and Bansal, Mukul S. and Carles, Annaick and Dixon, Jesse R. and Farh, Kai-How and Feizi, Soheil and Karlic, Rosa and Kim, Ah-Ram and Kulkarni, Ashwinikumar and Li, Daofeng and Lowdon, Rebecca and Elliott, GiNell and Mercer, Tim R. and Neph, Shane J. and Onuchic, Vitor and Polak, Paz and Rajagopal, Nisha and Ray, Pradipta and Sallari, Richard C. and Siebenthall, Kyle T. and {Sinnott-Armstrong}, Nicholas A. and Stevens, Michael and Thurman, Robert E. and Wu, Jie and Zhang, Bo and Zhou, Xin and Beaudet, Arthur E. and Boyer, Laurie A. and Jager, Philip L. De and Farnham, Peggy J. and Fisher, Susan J. and Haussler, David and Jones, Steven J. M. and Li, Wei and Marra, Marco A. and McManus, Michael T. and Sunyaev, Shamil and Thomson, James A. and Tlsty, Thea D. and Tsai, Li-Huei and Wang, Wei and Waterland, Robert A. and Zhang, Michael Q. and Chadwick, Lisa H. and Bernstein, Bradley E. and Costello, Joseph F. and Ecker, Joseph R. and Hirst, Martin and Meissner, Alexander and Milosavljevic, Aleksandar and Ren, Bing and Stamatoyannopoulos, John A. and Wang, Ting and Kellis, Manolis},
  month = feb,
  year = {2015},
  pages = {317-330}
}

@article{Consevage:1997:Basic,
  title = {{Basic elements of gene mapping and identification}},
  volume = {12},
  issn = {0268-4705},
  lccn = {00001573-199705000-00010},
  abstract = {The Human Genome Project has vastly facilitated the localization, identification, and characterization of disease-related genes by means of positional cloning. Application of this technique has elucidated the pathophysiology of several inheritable cardiovascular disorders and will ultimately change the clinical evaluation of and approach to these diseases. Over the next several years, efforts aimed at gene identification, DNA sequencing, correlation of genetic and physical maps, and manipulation of large segments of DNA will lead to identification of numerous candidate genes for positional analysis and will provide ample opportunity to identify the genetic abnormalities in other cardiovascular disorders. Because of the importance and clinical implications of these advances, a conceptual understanding of this methodology is essential to the practicing clinician., (C) Lippincott-Raven Publishers.},
  language = {English.},
  number = {3},
  journal = {Current Opinion in Cardiology},
  author = {Consevage, Michael and Cyran, Stephen},
  month = may,
  year = {1997},
  pages = {288-294},
  annote = {Interesting for historical reason. Published in the middle of the Human Genome Project (7 years after and 6 years before the completion)}
}

@article{Komajda:2001:heart,
  title = {The Heart of Genomics},
  volume = {7},
  copyright = {2001 Nature Publishing Group},
  issn = {1546-170X},
  doi = {10.1038/85420},
  abstract = {The completion of the Human Genome Project will provide much needed insight into the molecular basis of monogenic or complex cardiac disorders. But what are the prospects for using genomic information in diagnosis and treatment of cardiac diseases?},
  language = {en},
  number = {3},
  journal = {Nature Medicine},
  author = {Komajda, Michel and Charron, Philippe},
  month = mar,
  year = {2001},
  pages = {287-288},
  annote = {Summary: This article identify some prospects of genomic information in diagnosis and treatment of cardiac diseases

1. Identification of disease genes within associated loci. For example, chromosomal loci associated with arrhythmogenic right ventricular cardiomyopathy, dilated cardiomyopathy, artherosclerosis, etc. are found, but genes were not identified.

2. Risk stratification. For example hypertrophic cardiomyopathy is associated with mutations in multiple genes, but those in MYBPC3 are linked with higher death risk than those in MYH7.

3. More specific genetic-based classification of disease types

4. Pharmacogenomics help to individualize treatment for better response or to predict side effects.

An interesting example given in this article is Lamin A/C (encoded by the gene LMNA). Mutations in this gene have been found to link with various and seemingly unrelated disorders. The list of disorders have grown much longer since this publication. According to the GHR (Genetic Home Reference, NIH), there are now at least 11 disorders associated with mutations in LMNA. Many of them have unknown molecular basis. Although in this paper, this wide range of impact was attributed to the gene product having "multiple functions" it is more precise to state that such diverse impact is due to the variety of modifications (post-transcriptional and post-translational) as well as its binding partners in each organ and tissues.

Trang's thinking maybe LMNA can serve as an interesting example for how existing data can shed new lights if queried the right way.}
}

@article{Hiltunen:1999:Functional,
  title = {{Functional genomics and DNA array techniques in atherosclerosis research.  [Editorial]}},
  volume = {10},
  issn = {0957-9672},
  lccn = {00041433-199912000-00006},
  abstract = {DNA arrays are revolutionizing the analysis of gene expression and single nucleotide polymorphisms of genomic DNA. Currently, the expression of 10-15|X\% of human genes can be analysed simultaneously in a single experiment using cDNA or oligonucleotide-based format of DNA array. Alternatively, smaller DNA arrays with a limited number of selected genes, such as cytokines, growth factors or transcription factors, can be used. In concordance with Human Genome Project, after a few years, the DNA arrays will allow the analysis of expression of the whole human genome and will have a great impact on basic research, drug development and diagnostics. It is important to characterise mechanisms of atherosclerosis-related diseases at the level of gene expression so that new therapeutic strategies can be identified. With the aid of DNA array it is possible to identify multiple, simultaneous, transcriptional events that ameliorate or contribute to atherogenesis. The results are non-physical maps of the function, hierarchy and interactions of genetic programs. In this review we focus on DNA array technology and its applications in atherosclerosis research., (C) 1999 Lippincott Williams \& Wilkins, Inc.},
  language = {English.},
  number = {6},
  journal = {Current Opinion in Lipidology},
  author = {a Hiltunen, Mikko O. and a Nierni, Mari and a {Yla-Herttuala}, Seppo},
  month = dec,
  year = {1999},
  pages = {515-520}
}

@article{Roberts:2000:Myocardial,
  title = {{Myocardial Diseases}},
  volume = {102},
  issn = {0009-7322},
  lccn = {00003017-200011141-00005},
  language = {English.},
  number = {20},
  journal = {Circulation},
  author = {Roberts, Robert and Schwartz, Ketty},
  month = nov,
  year = {2000},
  keywords = {cardiomyopathies,genetics,hypertrophy}
}

@article{Simon:2013:Partners,
  title = {Partners and Post-Translational Modifications of Nuclear Lamins},
  volume = {122},
  issn = {0009-5915, 1432-0886},
  doi = {10.1007/s00412-013-0399-8},
  abstract = {Nuclear intermediate filament networks formed by A- and B-type lamins are major components of the nucleoskeleton that are required for nuclear structure and function, with many links to human physiology. Mutations in lamins cause diverse human diseases (`laminopathies'). At least 54 partners interact with human A-type lamins directly or indirectly. The less studied human lamins B1 and B2 have 23 and seven reported partners, respectively. These interactions are likely to be regulated at least in part by lamin post-translational modifications. This review summarizes the binding partners and post-translational modifications of human lamins and discusses their known or potential implications for lamin function.},
  language = {en},
  number = {1-2},
  journal = {Chromosoma},
  author = {Simon, Dan N. and Wilson, Katherine L.},
  month = mar,
  year = {2013},
  pages = {13-31}
}

@article{Wang:2016:Extraction,
  title = {Extraction and Analysis of Signatures from the {{Gene Expression Omnibus}} by the Crowd},
  volume = {7},
  issn = {2041-1723},
  doi = {10.1038/ncomms12846},
  abstract = {Gene expression data are accumulating exponentially in public repositories. Reanalysis and integration of themed collections from these studies may provide new insights, but requires further human curation. Here we report a crowdsourcing project to annotate and reanalyse a large number of gene expression profiles from Gene Expression Omnibus (GEO). Through a massive open online course on Coursera, over 70 participants from over 25 countries identify and annotate 2,460 single-gene perturbation signatures, 839 disease versus normal signatures, and 906 drug perturbation signatures. All these signatures are unique and are manually validated for quality. Global analysis of these signatures confirms known associations and identifies novel associations between genes, diseases and drugs. The manually curated signatures are used as a training set to develop classifiers for extracting similar signatures from the entire GEO repository. We develop a web portal to serve these signatures for query, download and visualization., 
A wealth of gene expression data is publicly available, yet is little use without additional human curation. Ma'ayan and colleagues report a crowdsourcing project involving over 70 participants to annotate and analyse thousands of human disease-related gene expression datasets.},
  journal = {Nature Communications},
  author = {Wang, Zichen and Monteiro, Caroline D. and Jagodnik, Kathleen M. and Fernandez, Nicolas F. and Gundersen, Gregory W. and Rouillard, Andrew D. and Jenkins, Sherry L. and Feldmann, Axel S. and Hu, Kevin S. and McDermott, Michael G. and Duan, Qiaonan and Clark, Neil R. and Jones, Matthew R. and Kou, Yan and Goff, Troy and Woodland, Holly and Amaral, Fabio M R. and Szeto, Gregory L. and Fuchs, Oliver and {Sch\"ussler-Fiorenza Rose}, Sophia M. and Sharma, Shvetank and Schwartz, Uwe and Bausela, Xabier Bengoetxea and Szymkiewicz, Maciej and Maroulis, Vasileios and Salykin, Anton and Barra, Carolina M. and Kruth, Candice D. and Bongio, Nicholas J. and Mathur, Vaibhav and Todoric, Radmila D and Rubin, Udi E. and Malatras, Apostolos and Fulp, Carl T. and Galindo, John A. and Motiejunaite, Ruta and J\"uschke, Christoph and Dishuck, Philip C. and Lahl, Katharina and Jafari, Mohieddin and Aibar, Sara and Zaravinos, Apostolos and Steenhuizen, Linda H. and Allison, Lindsey R. and Gamallo, Pablo and {de Andres Segura}, Fernando and Dae Devlin, Tyler and {P\'erez-Garc\'ia}, Vicente and Ma'ayan, Avi},
  month = sep,
  year = {2016},
  pmid = {27667448},
  pmcid = {PMC5052684},
  annote = {\subsection{Summary}

Crowdsourcing task: participants were asked to

1. identify GEO studies belonging to 1 of these types

* single-gene perturbation on mammalian cells

* single-drug perturbation on mammalian cells

* normal vs diseased tissues

2. extract metadata from the studies

3. compute differential expression using GEO2Enrichr (chrome extension)

Although not stated explicitly, it seemed the selected data sets are limited to microarray assays, so they can be processed uniformly (batch correction, then DEG calling).

Signatures were then sanitized by automated filters and manual inspection.

\subsection{Trang:}

1. From the manuscript, it sounds they have created a large data sets with quality annotation. The design of the microtask is a decent idea. However, the web app is disappointing. Given a query for "signature", for example "myocardial infarction", it will result in a list of signatures, each associated with a single GSE id, having their own list of up- and down-regulated genes. These lists do not seem to have resulted from an integrative analysis as described in the manuscript.

The list of up- and down-regulated genes are available upon clicking on the Enrichr icon. There are numerous design problems on this part, and in the Enrichr links that they lead to. On the Enrichr interface, multiple sources of other experiments are presented, each showing the top genes overlapping with the gene set under investigation. It takes some time to figure out what they're showing, and these plots do not give much insight, because very different types of assays are included here (for example ENCODE Histone modification, Co-expression with some specific TFs, etc.).

2. This platform gives me an idea on organizing GEO data sets. A critical requirement for exact retrieval is the consistency of data annotations. GEO has little requirement on standardizing data annotations, resulting in loosely structured metadata. For GEO to be exploited properly and effectively, it can be curated with controlled vocabulary, like ENCODE. These tasks may be designed for crowd-sourcing and/or scaled up with machine learning. There have been many ontologies developed for such purposes in biological research, for example the assay types (ChIP-seq, RNA-seq, etc.) can be annotated with OBI, UBERON for tissue sites, the biological sources can be annotated with CL for primary cell lines, etc.}
}

@article{Rouillard:2016:harmonizome,
  title = {The Harmonizome: A Collection of Processed Datasets Gathered to Serve and Mine Knowledge about Genes and Proteins},
  volume = {2016},
  shorttitle = {The Harmonizome},
  doi = {10.1093/database/baw100},
  abstract = {Abstract.  Genomics, epigenomics, transcriptomics, proteomics and metabolomics efforts rapidly
          generate a plethora of data on the activity and levels},
  language = {en},
  journal = {Database},
  author = {Rouillard, Andrew D. and Gundersen, Gregory W. and Fernandez, Nicolas F. and Wang, Zichen and Monteiro, Caroline D. and McDermott, Michael G. and Ma'ayan, Avi},
  month = jan,
  year = {2016}
}

@article{Strait:2012:AgingAssociated,
  title = {Aging-{{Associated Cardiovascular Changes}} and {{Their Relationship}} to {{Heart Failure}}},
  volume = {8},
  issn = {15517136},
  doi = {10.1016/j.hfc.2011.08.011},
  language = {en},
  number = {1},
  journal = {Heart Failure Clinics},
  author = {Strait, James B. and Lakatta, Edward G.},
  month = jan,
  year = {2012},
  pages = {143-164}
}

@article{Lakatta:2015:What,
  title = {So! {{What}}'s Aging? {{Is}} Cardiovascular Aging a Disease?},
  volume = {83},
  issn = {00222828},
  shorttitle = {So! {{What}}'s Aging?},
  doi = {10.1016/j.yjmcc.2015.04.005},
  language = {en},
  journal = {Journal of Molecular and Cellular Cardiology},
  author = {Lakatta, Edward G.},
  month = jun,
  year = {2015},
  pages = {1-13}
}

@article{North:2012:Intersection,
  title = {The {{Intersection Between Aging}} and {{Cardiovascular Disease}}},
  volume = {110},
  issn = {0009-7330, 1524-4571},
  doi = {10.1161/CIRCRESAHA.111.246876},
  abstract = {The average lifespan of humans is increasing, and with it the percentage of people entering the 65 and older age group is growing rapidly and will continue to do so in the next 20 years. Within this age group, cardiovascular disease will remain the leading cause of death, and the cost associated with treatment will continue to increase. Aging is an inevitable part of life and unfortunately poses the largest risk factor for cardiovascular disease. Although numerous studies in the cardiovascular field have considered both young and aged humans, there are still many unanswered questions as to how the genetic pathways that regulate aging in model organisms influence cardiovascular aging. Likewise, in the molecular biology of aging field, few studies fully assess the role of these aging pathways in cardiovascular health. Fortunately, this gap is beginning to close, and these two fields are merging together. We provide an overview of some of the key genes involved in regulating lifespan and health span, including sirtuins, AMP-activated protein kinase, mammalian target of rapamycin, and insulin-like growth factor 1 and their roles regulating cardiovascular health. We then discuss a series of review articles that will appear in succession and provide a more comprehensive analysis of studies carried out linking genes of aging and cardiovascular health, and perspectives of future directions of these two intimately linked fields.},
  language = {en},
  number = {8},
  journal = {Circulation Research},
  author = {North, B. J. and Sinclair, D. A.},
  month = apr,
  year = {2012},
  pages = {1097-1108}
}

@article{Claverie:1999:Computational,
  title = {Computational {{Methods}} for the {{Identification}} of {{Differential}} and {{Coordinated Gene Expression}}},
  volume = {8},
  issn = {0964-6906},
  doi = {10.1093/hmg/8.10.1821},
  abstract = {Abstract.  With the first complete `draft' of the human genome sequence expected for Spring 2000, the three basic challenges for today's bioinformatics are more},
  language = {en},
  number = {10},
  journal = {Human Molecular Genetics},
  author = {Claverie, Jean-Michel},
  month = jan,
  year = {1999},
  pages = {1821-1832},
  annote = {Among the first to introduce computational methods for the analysis of early day gene expression data, this paper outlined the three approaches that are still popular in today transcriptomics studies: (1) DEG analysis, (2) Co-expression analysis and (3) gene clustering and subsequent definition of biological pathways.}
}

@article{Comroe:1974:Ben,
  title = {Ben {{Franklin}} and {{Open Heart Surgery}}},
  volume = {35},
  issn = {0009-7330, 1524-4571},
  doi = {10.1161/01.RES.35.5.661},
  language = {en},
  number = {5},
  journal = {Circulation Research},
  author = {Comroe, J. H. and Dripps, R. D.},
  month = nov,
  year = {1974},
  pages = {661-669},
  annote = {[object Object]}
}


